Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
- Published In:
- Liver international : official journal of the International Association for the Study of the Liver, 45(4), e16174 (2025)
- Authors:
- Asselah, Tarik, Lampertico, Pietro(2), Aleman, Soo, Bourlière, Marc, Streinu-Cercel, Adrian, Bogomolov, Pavel, Morozov, Viacheslav, Stepanova, Tatiana, Lazar, Stefan, Manuilov, Dmitry, Mercier, Renee-Claude, Tseng, Steve, Ye, Lei, Flaherty, John F, Osinusi, Anu, Da, Ben L, Chee, Grace M, Lau, Audrey H, Brunetto, Maurizia R, Wedemeyer, Heiner
- Database ID:
- RPEP-10004
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10004APA
Asselah, Tarik; Lampertico, Pietro; Aleman, Soo; Bourlière, Marc; Streinu-Cercel, Adrian; Bogomolov, Pavel; Morozov, Viacheslav; Stepanova, Tatiana; Lazar, Stefan; Manuilov, Dmitry; Mercier, Renee-Claude; Tseng, Steve; Ye, Lei; Flaherty, John F; Osinusi, Anu; Da, Ben L; Chee, Grace M; Lau, Audrey H; Brunetto, Maurizia R; Wedemeyer, Heiner. (2025). Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.. Liver international : official journal of the International Association for the Study of the Liver, 45(4), e16174. https://doi.org/10.1111/liv.16174
MLA
Asselah, Tarik, et al. "Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.." Liver international : official journal of the International Association for the Study of the Liver, 2025. https://doi.org/10.1111/liv.16174
RethinkPeptides
RethinkPeptides Research Database. "Bulevirtide Monotherapy Is Safe and Well Tolerated in Chroni..." RPEP-10004. Retrieved from https://rethinkpeptides.com/research/asselah-2025-bulevirtide-monotherapy-is-safe
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.